Engineering HLA-DQ–specific CAR Tregs to selectively suppress anti-donor immune responses at sites of graft inflammation, this project seeks a more precise, durable alternative to broad immunosuppression in transplantation.
Exploiting a newly discovered PD-1 dimerization mechanism, this project engineers monoclonal antibodies to more effectively suppress overactive T cells — offering a novel immune tolerance strategy for autoimmune diseases.
Developing a bioavailable DNAseIL3 biologic to degrade pathogenic autoantibodies and treat lupus and related autoimmune diseases.
Identifying the signaling pathways that drive rhinovirus-induced airway inflammation to find small molecule drugs that prevent asthma attacks.
Restoring thromboangioplasticity in antiphospholipid syndrome by developing recombinant proteins that counteract harmful anti-annexin V antibodies.
Repurposing nuclear-penetrating autoantibodies from lupus and scleroderma patients as potent, safe inhibitors of pathogenic NETosis.
Designing synthetic antigens that reprogram allergic immune memory toward durable, healthy responses — moving precision allergy vaccines toward the clinic.
Developing novel multivalent small molecules that selectively silence or eliminate the autoantibody-producing B cells driving autoimmune disease.
Developing 10E5-1, an anti-activin A antibody delivered via mRNA-LNP, to suppress pathogenic antibody production and treat rheumatoid arthritis through a novel mechanism.
Identifying the autoantigens and T cell clonotypes driving immune attack in aplastic anemia to enable more precise diagnostics and targeted therapies.
